Protocol Ledger

NCT07192952 · Phase III · RECRUITING

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

Interventional Phase III clinical trial protocol NCT07192952 sponsored by Bayer in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-01 Enrollment: 117 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07192952
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)117 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07192952
Protocol FieldVerified Registry Value
NCT IdentifierNCT07192952
Consolidated Lead SponsorBayer
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment117 participants (ESTIMATED)
Registered Start Date2026-06-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI